145 
1 individual IBC's. It is our hope that results will con- 
2 tribute to a recombinant DNA research policy that takes 
3 into account the many aspects of committee structure and 
4 function which influence the operation of IBC's and their 
5 openness to various views. With such information, future 
6 recombinant DNA regulatory policies, specifically those 
I which expand the responsibilities of IBC's, could draw 
g on fact, not assumptions about the effectiveness and 
9 efficiency of this method of regulation. 
10 I would urge that the NIH and the HEW endorse 
II a nd support such a study. 
12 Thank you. 
13 MR. LIBASSI: You are not suggesting, however, 
14 that we make no changes pending the completion of your 
15 study? 
16 MS. PFUND : No, I think that within future 
17 iterations of the guidelines there should be a nechanism 
18 to include information about the efficiency of the 
19 regulatory structure. 
20 MR. LIBASSI: Thank you. 
21 Donald Brown? 
22 DR. BROWN: My name is Donald Brown. I am a 
23 medical doctor. I have done biology on microorganisms, 
24 and on animal genes for the past 15 or 20 years. I have 
25 been involved in the discussions of recombinant DNA research 
I 
» 
[ 237 ] 
I 
